We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
-2.94%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$119B
AUM Growth
-$2.4B
Cap. Flow
+$2.12B
Cap. Flow %
1.78%
Top 10 Hldgs %
24.78%
Holding
3,988
New
162
Increased
1,714
Reduced
1,756
Closed
200

Top Sells

Rank Stock Value
1
RTX icon
RTX Corp
RTX
+$99.6M
2
AAPL icon
Apple
AAPL
+$88.3M
3
MBB icon
iShares MBS ETF
MBB
+$85.4M
4
MTUM icon
iShares MSCI USA Momentum Factor ETF
MTUM
+$51.6M
5
CSCO icon
Cisco
CSCO
+$43.2M

Sector Composition

Rank Sector Weight
1 Technology 14.94%
2 Financials 8.89%
3 Healthcare 8.4%
4 Industrials 6.56%
5 Consumer Discretionary 5.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HNST icon
3701
The Honest Company
HNST
$551M
$26.7K ﹤0.01%
21,226
-1,250
-6% -$1.83K
LX
3702
LexinFintech Holdings
LX
$239M
$26.3K ﹤0.01%
11,900
AIV
3703
CALL
Aimco
AIV
$381M
$25K ﹤0.01%
5,000
DWSN icon
3704
Dawson Geophysical
DWSN
$137M
$24.6K ﹤0.01%
10,593
-4,000
-27% -$7.93K
ONDS icon
3705
Ondas Inc
ONDS
$5.55B
$23.9K ﹤0.01%
39,255
-4,876
-11% -$5.37K
CDE icon
3706
Coeur Mining
CDE
$19.4B
$23.9K ﹤0.01%
10,750
-14,100
-57% -$36.8K
SPCE icon
3707
Virgin Galactic
SPCE
$501M
$23.5K ﹤0.01%
652
+92
+16% +$5.49K
NGM
3708
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$23.5K ﹤0.01%
21,923
-310
-1% -$642
AKBA icon
3709
Akebia Therapeutics
AKBA
$244M
$23.1K ﹤0.01%
20,221
+8,619
+74% +$11.1K
CVM icon
3710
CEL-SCI Corp
CVM
$25.9M
$23K ﹤0.01%
613
DHY
3711
Credit Suisse High Yield Credit Fund
DHY
$242M
$22.6K ﹤0.01%
12,000
GIS icon
3712
PUT
General Mills
GIS
$19.9B
$22K ﹤0.01%
400
UP icon
3713
Wheels Up
UP
$194M
$21.9K ﹤0.01%
+529
New +$21.3K
ESPR
3714
DELISTED
Esperion Therapeutics
ESPR
$21.3K ﹤0.01%
21,714
+4,578
+27% +$6.62K
JVA icon
3715
Coffee Holding Co
JVA
$20M
$20.9K ﹤0.01%
24,000
-15,000
-38% -$19.2K
BCEL
3716
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$20.2K ﹤0.01%
77,500
CISO
3717
CISO Global
CISO
$11.5M
$19.7K ﹤0.01%
9,395
+667
+8% +$1.76K
NUVB icon
3718
Nuvation Bio
NUVB
$2.24B
$19.7K ﹤0.01%
14,710
-3,000
-17% -$4.99K
QTTB icon
3719
Q32 Bio
QTTB
$460M
$18.6K ﹤0.01%
884
AZ icon
3720
A2Z Smart Technologies
AZ
$294M
$16.5K ﹤0.01%
4,000
CRGE
3721
DELISTED
Charge Enterprises, Inc. Common Stock
CRGE
$16.1K ﹤0.01%
32,440
-16,100
-33% -$12.1K
HYLN icon
3722
Hyliion Holdings
HYLN
$788M
$14.9K ﹤0.01%
12,600
+2,500
+25% +$3.74K
SNCR
3723
DELISTED
Synchronoss Technologies
SNCR
$14.6K ﹤0.01%
1,691
SKYX icon
3724
SKYX Platforms
SKYX
$163M
$14.2K ﹤0.01%
10,000
VXRT
3725
DELISTED
Vaxart
VXRT
$13.2K ﹤0.01%
17,488
-250
-1% -$190

Similar funds

Raymond James & Associates's Q3 2023 Portfolio in Review

As of Q3 2023, Raymond James & Associates held 3,988 positions worth $119B, down 2% from $121B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Raymond James & Associates's Q3 2023 filing shows 162 new, 1,714 increased, 1,756 reduced and 200 closed positions. Its largest new stake was InterContinental Hotels: 102,555 shares worth $7.67M. The largest sale was RTX Corp, an estimated $99.6M.

By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 15% a quarter earlier, followed by Financials and Healthcare.

  • Raymond James & Associates's largest Q3 2023 buy was InterContinental Hotels: 102,555 shares worth $7.67M.
  • Raymond James & Associates added most to Vanguard S&P 500 ETF in Q3 2023, an estimated $630M increase.
  • Raymond James & Associates's biggest Q3 2023 reduction was RTX Corp, cutting an estimated $99.6M.
  • Raymond James & Associates fully exited Magellan Midstream Partners, L.P. in Q3 2023, selling an estimated $17.3M.
  • Raymond James & Associates's ten largest holdings make up 25% of its $119B portfolio in Q3 2023.
  • Raymond James & Associates opened 162 new positions and closed 200 in Q3 2023.
  • Raymond James & Associates's portfolio value fell 2% quarter-over-quarter to $119B.

Based on Raymond James & Associates's 13F filing for Q3 2023, filed 24 Oct 2023.